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As dietary saturated fatty acids are associated with metabolic and cardiovascular disease,
a potentially interesting strategy to reduce disease risk is modification of the quality of fat
consumed. Vegetable oils represent an attractive target for intervention, as they largely
determine the intake of dietary fats. Furthermore, besides potential health effects conferred
by the type of fatty acids in a vegetable oil, other minor components (e.g. phytochemicals)
may also have health benefits. Here, we investigated the potential long-term health effects
of isocaloric substitution of dietary fat (i.e. partial replacement of saturated by unsaturated
fats), as well as putative additional effects of phytochemicals present in unrefined (virgin) oil
on development of non-alcoholic fatty liver disease (NAFLD) and associated atherosclero-
sis. For this, we used pumpkin seed oil, because it is high in unsaturated fatty acids and a
rich source of phytochemicals.
Methods
ApoE*3Leiden mice were fed aWestern-type diet (CON) containing cocoa butter (15% w/
w) and cholesterol (1% w/w) for 20 weeks to induce risk factors and disease endpoints. In
separate groups, cocoa butter was replaced by refined (REF) or virgin (VIR) pumpkin seed
oil (comparable in fatty acid composition, but different in phytochemical content).
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Results
Both oils improved dyslipidaemia, with decreased (V)LDL-cholesterol and triglyceride levels
in comparison with CON, and additional cholesterol-lowering effects of VIR over REF.
While REF did not affect plasma inflammatory markers, VIR reduced circulating serum amy-
loid A and soluble vascular adhesion molecule-1. NAFLD and atherosclerosis development
was modestly reduced in REF, and VIR strongly decreased liver steatosis and inflammation
as well as atherosclerotic lesion area and severity.
Conclusions
Overall, we show that an isocaloric switch from a diet rich in saturated fat to a diet rich in
unsaturated fat can attenuate NAFLD and atherosclerosis development. Phytochemical-
rich virgin pumpkin seed oil exerts additional anti-inflammatory effects resulting in more pro-
nounced health effects.
Introduction
Cardiometabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular
disease (CVD) constitute a major health burden in modern societies. Accumulating evidence
suggests that NAFLD, besides increasing liver morbidity and mortality, is associated with
development of atherosclerosis, the major underlying pathology of CVD [1]. As dyslipidaemia
and chronic inflammation are recognised to drive the development of NAFLD as well as ath-
erosclerosis [2–4], dietary regimens that influence one or both of these risk factors may be of
great preventive and possibly even therapeutic benefit. Support for this concept comes from
epidemiological and experimental studies that show that the type of dietary fat consumed plays
an important role in the development of both NAFLD and associated CVD (reviewed in [5,
6]). Therefore, a potentially interesting strategy to reduce cardiometabolic risk is a modification
of the quality of fat in diets. This is further supported by results from a recent systematic review
indicating that partial replacement of saturated fat by unsaturated fat may reduce CVD risk
[7].
The daily intake of dietary fats is largely determined by vegetable oils, which makes them an
attractive target for intervention. The more so, since besides potential health effects conferred
by the type of fatty acids in a vegetable oil, other minor components of an oil (e.g. phytochemi-
cals) may also significantly contribute to cardiometabolic health. Typically, vegetable oils are
consumed in their fully refined form that consists almost exclusively of triglycerides. Virgin
oils on the other hand, the completely unrefined first press form of an oil, are rich in a collec-
tion of phytochemicals (e.g. vitamins E and K, phytosterols and polyphenols) that may influ-
ence the critical risk factors dyslipidaemia as well as inflammation [8, 9].
Herein we investigated the potential long-term health effects of substitution of dietary satu-
rated fat by unsaturated fat from refined oil, as well as putative additional effects of the unre-
fined counterpart rich in phytochemicals (virgin oil). For this, we used pumpkin seed oil,
because it is high in unsaturated fatty acids (about 80%) and known to contain large amounts
of phytochemicals [10, 11]. In short-term studies, pumpkin seed oil has been shown to reduce
surrogate markers of liver health [12] and improve dyslipidaemia [13–15]. However, potential
anti-inflammatory properties have not been examined and its effects on cardiometabolic dis-
ease endpoints are unknown.
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The ApoE3Leiden (E3L) mouse is a well-established diet-inducible model for NAFLD [16]
and atherosclerosis [17]. The model develops human-like dyslipidaemia, inflammation and
disease endpoints in response to a well-defined Western-type diet, containing cocoa butter
(±60% saturated fat) as the major fat source [17, 18]. This diet also contains cholesterol (1% w/
w), which is required for induction of dyslipidaemia, inflammation and disease endpoints [16,
18, 19]. Groups of E3L mice were fed the Western-type control diet (CON) or pumpkin seed
oil-substituted diets, REF (refined oil) and VIR (virgin oil) for 20 weeks, all of which contained
1% cholesterol. The refined and virgin pumpkin seed oils were comparable in fatty acid profile
but differed in phytochemical content. This allowed us to define the health effects of refined
pumpkin seed oil, as well as the additional effects of the phytochemicals present in its unrefined
counterpart. Plasma lipids and markers of inflammation were monitored over time and
NAFLD and atherosclerosis endpoints were scored according to established human grading
systems ([20–22]). Results from this study indicate that an isocaloric switch from a diet rich in
saturated fat to a diet rich in unsaturated fat has beneficial effects on risk factors, and that phy-
tochemical-rich virgin oil has additional anti-inflammatory properties and more strongly
reduces disease endpoints.
Materials and Methods
All animal experiments were approved by an independent Ethical Committee on Animal Care
and Experimentation (DEC-Zeist, the Netherlands) and were in compliance with European
Community specifications regarding the use of laboratory animals. Female ApoE3Leiden
transgenic (E3L) mice were obtained from the breeding facility of TNOMetabolic Health
Research, Leiden, the Netherlands, and were characterised for expression of human APOE by
ELISA. 12-week old E3L mice were matched into 3 groups based on plasma cholesterol and tri-
glycerides. All animals were group-housed (3–4 mice per cage) in the SPF animal facility of
TNOMetabolic Health Research, in a temperature-controlled room on a 12 hour light/dark
cycle and had free access to food and water. Diets were based on a standardised atherogenic
Western-type diet (WTD) that contains 15% cocoa butter, 1% corn oil, 40.5% sucrose, 20%
acid casein, 10% corn starch and 6.2% cellulose (all w/w; diet-T; AB-Diets, Woerden, the Neth-
erlands), supplemented with 1% (w/w) cholesterol (Sigma-Aldrich, Zwijndrecht, the Nether-
lands). Control mice (CON, n = 18) were fed this standard WTD, while the treatment groups
received the WTD with 9% (w/w of total diet) of the cocoa butter replaced by either 9% refined
pumpkin seed oil (REF, n = 15; Bunge Ltd., White Plains, USA) or 9% virgin pumpkin seed oil
(VIR, n = 15; Bunge Ltd). As the cholesterol in this diet is required to induce inflammation and
dyslipidaemia [16, 18, 19], the cholesterol concentration was the same (1%) in all three groups.
Detailed methods of the analysis of the composition of the cocoa butter and pumpkin seed
oils are described in S1 Text. Briefly, the fatty acid composition was determined by gas chroma-
tography, the total phenolic content was determined spectrophotometrically by the Folin-Ciol-
calteau method, and individual phenolic content of the pumpkin seed oils was determined by
LC-QTOF-MS.
Food intake was measured per cage (3–4 mice per cage) every 4 weeks, expressed as the
average food intake per mouse per day. The energy content of the diets was determined by
bomb calorimetry. Blood samples were collected from the tail vein after a 4h fasting period for
EDTA plasma isolation at week 0, 3, 6, 12 and 20 of the study. Total plasma cholesterol and tri-
glyceride levels were measured in these fasted plasma samples by commercially available enzy-
matic assays (cholesterol CHOD-PAP 11491458 and triglycerides GPO-PAP 11488872, Roche,
Woerden, The Netherlands). For lipoprotein profile analysis, pooled plasma samples were frac-
tionated using an ÅKTA fast protein liquid chromatography system (Pharmacia, Roosendaal,
Pumpkin Seed Oil Reduces Cardiometabolic Disease
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the Netherlands) and analysed as reported [23]. Plasma levels of soluble vascular adhesion mol-
ecule 1 (sVCAM-1; R&D Systems, Abingdon, UK) and serum amyloid A (SAA; Life Technolo-
gies, Bleiswijk, the Netherlands) were determined by ELISA. ALAT and ASAT levels were
measured in serum (unfasted sample from terminal blood, specified below) using a spectro-
photometric activity assay (Reflotron Plus system, Roche). After 20 weeks of dietary treatment,
mice were sacrificed by CO2 asphyxiation and blood was collected via cardiac puncture for
serum collection (unfasted). Hearts and livers were collected, and fixed in formalin and embed-
ded in paraffin for atherosclerosis analysis (heart) and NAFLD analysis (liver).
Histological analysis of NAFLD and atherosclerosis development
For NAFLD analysis, 3 μm liver sections (medial lobe) were stained with haematoxylin and
eosin and analysed blindly using an adapted scoring method for human NAFLD [20, 24].
Briefly, steatosis was expressed as the percentage of the total liver cross section affected by
microvesicular steatosis or macrovesicular steatosis. Hepatic inflammation was analysed by
counting the number of inflammatory foci per section at a 100× magnification.
Atherosclerosis was analysed blindly in 4 serial cross sections (5 μm, at 50 μm intervals) of
the valve area of the aortic root. Cross sections were stained with haematoxylin-phloxine-saf-
fron (HPS) for morphometric analysis of lesion number and area (using cell^D software, ver-
sion 2.7; Olympus Soft Imaging Solutions, Hamburg, Germany) and analysis of lesion severity.
Lesion severity was scored according to the classification of the American Heart Association
(AHA) [21, 22]. This scoring system was used to distinguish five lesion types: Type I (early
fatty streak): up to ten foam cells in the intima, no other changes; Type II (regular fatty streak):
ten or more foam cells in the intima, no other changes; Type III (mild plaque): foam cells in the
intima with presence of a fibrotic cap; Type IV (moderate plaque): progressive lesion, infiltra-
tion into media, elastic fibres intact; Type V (severe plaque): structure of media severely dis-
rupted with fragmented elastic fibres, cholesterol crystals, calcium deposits and necrosis may
be present. The lesional macrophage content was assessed by immunohistochemical staining
of MAC-3 (CD107b) positive cells (purified rat anti-mouse CD107b antibody, BD Biosciences,
Breda, the Netherlands) in cross-sections adjacent to those used for the atherosclerosis analysis.
The MAC-3 positive area for each individual plaque was measured using an automated macro
in the image processing software ImageJ (version 1.48, NIH, Bethesda, MD, USA; [25]) and
expressed as the percentage of total plaque area that was positively stained for MAC-3. The
number of lesions was counted in 4 cross sections and expressed as the average per cross-sec-
tion. Furthermore, the number of lesion-free (undiseased) segments was counted and
expressed as a percentage of the total number of segments (N.B. each aortic cross-section is
divided into 3 segments that are demarcated by the aortic valves, making a total of 12 segments
analysed per mouse).
Hepatic gene expression analyses
Total RNA was extracted from liver tissue using RNA Bee Total RNA Isolation Kit (Bio-Con-
nect, Huissen, the Netherlands). Spectrophotometric analysis of RNA concentration was per-
formed using Nanodrop 1000 (Isogen Life Science, De Meern, the Netherlands) and quality of
RNA was assessed using a 2100 Bioanalyzer (Agilent Technologies, Amstelveen, the Nether-
lands). cDNA was synthesised using a High Capacity RNA-to-cDNA™ Kit (Life Technologies,
Bleiswijk, the Netherlands). Hepatic gene expression analyses were performed by RT-PCR on a
7500 Fast Real-Time PCR System (Applied Biosystems by Life Technologies) using TaqMan1
Gene Expression Assays (Life Technologies). Transcripts were quantified using TaqMan1 Gene
Expression Assays (Life Technologies) and the following primer/probe-sets for Srebf1
Pumpkin Seed Oil Reduces Cardiometabolic Disease
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(Mm00550338_m1), Fasn (Mm00662319_m1), Dgat1 (Mm00515643_m1), Ppara (Mm0044
0939_m1), Cpt1a (Mm01231183_m1), Acox1 (Mm00443579_m1), Ccl2 (Mm00441242_m1),
Tnf (Mm00443258_m1), Il1b (Mm00434228_m1) and the endogenous controlsHprt (Mm00
446968_m1) and Ppif (Mm01273726_m1). Changes in gene expression were calculated using
the comparative Ct (ΔΔCt) method and expressed as fold-change relative to CON.
Hepatic lipid analysis
Lipids were extracted from liver homogenates using the Bligh and Dyer method [26] and sepa-
rated by high performance thin layer chromatography (HPTLC) on silica gel plates as
described previously [27]. Lipid spots were stained with color reagent (5g MnCl24H2O, 32ml
95–97% H2SO4 added to 960ml CH3OH:H2O 1:1 v/v) and triglycerides, cholesteryl esters and
free cholesterol were quantified using TINA version 2.09 software (Raytest, Straubenhardt,
Germany).
Statistical analyses
All data are presented as mean±SEM. Statistical analyses were performed using SPSS software
(version 22, IBM, Armonk, USA). For normally distributed variables, significance of differ-
ences between groups was tested by one-way ANOVA, followed by Fisher's Least Significant
Difference (LSD) Post-Hoc Test. In case of heterogeneity between groups, variables were ana-
lysed by ANOVA using Brown-Forsythe for differences between groups followed by Dunnett’s
T3 Post-Hoc Test. Non-normally distributed variables were tested by non-parametric Kruskal-
Wallis test followed by Mann-Whitney U tests. To test the hypothesis that both pumpkin seed
oils may have beneficial effects relative to control and that the virgin oil may have additional
beneficial effects over its refined counterpart, a one-sided p-value0.05 was considered statisti-
cally significant.
Results
The refined and virgin pumpkin seed oils used in this study were comparable in fatty acid com-
position (Table 1). Both oils contained 81% unsaturated fatty acids, most of which consisted of
linoleic acid (C18:2n-6, 64%) and oleic acid (C18:1n-9, 17%). The virgin oil contained more
phytochemicals than its refined counterpart (Table 2). Virgin pumpkin seed oil was rich in
benzoic acid, vanillic acid, ferulic acid, rutin and p-coumaric acid, many of which were below
the detection limit in the refined oil. Overall, the total phenolic content was 7.7-fold higher in
the virgin oil than in the refined oil.
To investigate potential health effects of these oils on NAFLD and atherosclerosis, E3L mice
were fed a standardised Western type control diet (CON) or the same diet substituted with 9%
(w/w) refined pumpkin seed oil (REF) or 9% (w/w) virgin pumpkin seed oil (VIR) for 20
weeks. All diets contained 1% (w/w) cholesterol and were comparable in energy content as
quantified by bomb calorimetry (CON: 20.2 kJ/g, REF: 20.0 kJ/g and VIR: 20.4 kJ/g) and food
intake was comparable between groups (S1 Fig). The treatments were well tolerated and body
weight increased slightly over time (percentage body weight gain relative to t = 6: CON: 12.3
±1.3%, REF: 8.9±1.8%, VIR: 11.1±1.6%, n.s.) in all groups (S1 Fig).
Both pumpkin seed oils improve dyslipidaemia, with additional beneficial
effects of virgin oil over refined oil
Plasma cholesterol levels rose rapidly in CON animals within the first 3 weeks and remained
relatively stable until the end of the study (Fig 1a) with an average of 19.20±0.39 mM. Both
Pumpkin Seed Oil Reduces Cardiometabolic Disease
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REF and VIR animals had significantly lower fasting plasma cholesterol levels compared with
CON at all time points (Fig 1a). Area under the curve (AUC) analysis of the plasma cholesterol
levels throughout the study period showed a significantly lower AUC for cholesterol in VIR
(293.6±13.6 AU),than in REF (328.8±7.0 AU, p0.05, Fig 1b), indicating additional choles-
terol-lowering properties of VIR. These cholesterol-lowering effects were mainly confined to
the VLDL-sized particles (Fig 1c). In CON animals, fasting plasma triglycerides remained at a
Table 1. Fatty acid composition of cocoa butter and refined and virgin pumpkin seed oil.
Cocoa butter Reﬁned pumpkin seed oil Virgin pumpkin seed oil
Poly-unsaturated fatty acids (% of total) 2.8 64.4 64.0
C18:2 Linoleic acid (n-6) 2.7 64.1 63.9
C18:3 alpha-Linolenic acid (n-3) 0.1 0.3 0.1
Mono-unsaturated fatty acids (% of total) 33.0 17.0 17.8
C18:1 Oleic acid 32.8 16.6 17.1
C16:1 Palmitoleic acid 0.2 0.3 0.2
C20:1 Eicosanoic acid n.d. 0.1 0.4
Saturated fatty acids (% of total) 63.7 18.0 18.1
C16:0 Palmitic acid 26.7 12.8 12.8
C18:0 Stearic acid 35.7 4.5 4.5
C20:0 Arachidic acid (Eicosanoic acid) 1.0 0.3 0.3
C22:0 Behenic acid (Docosanoic acid) 0.2 0.2 0.2
C14:0 Myristic acid (Tetradecanoic acid) 0.1 0.1 0.1
C24:0 Lignoceric acid (Tetracosanoic acid) n.d. 0.1 0.1
Trans fatty acids (% of total) n.d. 0.7 0.2
C18:2T Trans linoleic acid n.d. 0.7 0.2
n.d. = not detected.
doi:10.1371/journal.pone.0139196.t001
Table 2. Phytochemical content of cocoa butter and refined and virgin pumpkin seed oil
Cocoa butter Reﬁned pumpkin seed oil Virgin pumpkin seed oil
Tocopherols (ppm) 246 386 577
Tocotrienols (ppm) 7 123 121
Vitamin K (μg/100g) 3.5 52.3 68.0
Total phenolic content (mg gallic acid/kg oil) 8.3 3.6 27.7
Benzoic acid (μM) n.d. 0.1 19.3
p-coumaric acid (nM) n.d. n.d. 200
Vanillic acid (nM) 791 n.d. 300
Ferulic acid (nM) n.d. n.d. 300
Rutin (nM) n.d. n.d. 4
Isomer of 3-hydroxybenzoic acid (nM) n.d. 50 8000
Isomer of protocatechuic acid (nM) n.d. n.d. 700
Isomer of caffeic acid (nM) n.d. n.d. 60
Isomer of ferulic acid (nM) 456 30 100
Isomer of naringenin (nM) 162 n.d. 2100
Isomer of 4-hydroxyphenylpropionic (nM) 522 10 700
n.d. = not detected, Tocopherols = sum of α, β, γ and δ (δ was n.d.). Tocotrienols = sum of α, γ and δ.
doi:10.1371/journal.pone.0139196.t002
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Fig 1. Refined and virgin pumpkin seed oils have beneficial effects on plasma lipids in cholesterol-fed
ApoE*3Leidenmice.Mice were fed aWestern type diet (CON) containing cocoa butter (15% w/w of diet) for
20 weeks. The cocoa butter was in part replaced by refined pumpkin seed oil (REF) or virgin pumpkin seed oil
(VIR) (each 9% w/w of diet). A: Plasma cholesterol levels over the course of the study, showing lower levels
in REF and VIR-fed animals. B: Area under the curve analysis (AUC, expressed in arbitrary units; AU) of
plasma cholesterol levels (t = 0 until t = 20 weeks) shows additional cholesterol-lowering effect of VIR
compared with REF. C: Lipoprotein profile for cholesterol distribution in VLDL, LDL and HDL-sized particles
shows cholesterol-lowering effect mainly confined to VLDL-sized particles. D: Plasma triglycerides over the
course of the study were lowered by both REF and VIR. E: Area under the curve analysis of plasma
triglyceride levels (t = 0 until t = 20 weeks) shows a reduction by VIR and REF. Data are mean±SEM. *
p0.05, ** p0.01, *** p0.001 compared with CON. # p0.05, ## p0.01 for VIR compared with REF.
doi:10.1371/journal.pone.0139196.g001
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stable and elevated level during the study (average 2.67±0.09 mM, (Fig 1d). Both pumpkin seed
oils decreased fasting plasma triglyceride levels within the first 3 weeks of the study and levels
remained stable at this low level thereafter (average REF 1.79±0.08 mM, average VIR 1.63±0.07
mM, Fig 1d). Overall, VIR treatment did not have additional beneficial effects on plasma tri-
glyceride levels relative to REF as is also shown by results from the AUC analysis for plasma tri-
glyceride levels (Fig 1e). Together, these results indicate that the observed lipid-lowering effects
are predominantly attributable to the replacement of saturated by unsaturated dietary fat.
Virgin pumpkin seed oil reduces circulating markers of liver and vascular
inflammation
CON diet induced plasma levels of SAA, a marker of liver inflammation, from 5.65±0.34 μg/ml
at t = 0 to 10.55±1.21 μg/ml at the end of the study (Fig 2a). SAA levels in REF animals were
comparable to CON, while VIR attenuated SAA induction and plasma levels were significantly
lower than CON at t = 12 and t = 20 weeks (6.77±0.44 μg/ml at t = 20, -36%, p0.01, Fig 2a).
In line with this effect on SAA, serum levels of the hepatocellular damage markers ASAT and
ALAT were not affected by REF, and VIR significantly reduced both ASAT (p0.05) and
ALAT levels (p0.05) (Fig 2b and 2c). Besides inducing liver inflammation, CON diet also
gradually induced plasma levels of vascular inflammation marker sVCAM-1 from 2.45
±0.09 μg/ml at t = 0 to 4.01±0.12 μg/ml at t = 20 weeks (Fig 2d). Levels of sVCAM-1 were not
affected by REF, but VIR animals showed lower sVCAM-1 throughout the study period and
this effect reached significance at t = 20 weeks (3.47±0.14 μg/ml, -14%, p0.05, Fig 2d). These
data show that the phytochemicals in virgin pumpkin seed oil are responsible for the observed
anti-inflammatory effects on circulating liver and vascular inflammation markers.
Virgin pumpkin seed oil attenuates development of NAFLD
Refined pumpkin seed oil reduced liver weight by 12% (CON: 5.9±0.2% of terminal body
weight, REF: 5.2±0.2%, p0.05, Fig 3a) and this effect was even stronger in VIR (-19%), with
liver weights reduced to 4.8±0.1% of terminal body weight (p0.01, Fig 3a). Histological exam-
ination of the livers from CON animals revealed that NAFLD developed in these mice up to
the stage of non-alcoholic steatohepatitis (NASH). CON mice displayed distinctive morpho-
logical hallmarks of NASH (pronounced steatosis and lobular infiltration of inflammatory
cells) and the observed pathology was less severe in REF and VIR animals (representative pho-
tomicrographs shown in Fig 3b). Quantitative scoring of NAFLD revealed that macrovesicular
steatosis tended to be lower in REF (-26%, p = 0.08) and was significantly reduced with VIR
(-45%, p0.01) (Fig 3c). Microvesicular steatosis was less pronounced in both REF and VIR
(-41% and -65%, respectively), but this effect did not reach statistical significance (S2 Fig). Bio-
chemical analysis of hepatic lipid levels confirmed the histologically observed antisteatotic
effects of the pumpkin seed oils, showing reduced hepatic triglyceride content in both REF and
VIR (-17%, p0.01 and -23%, p0.001 respectively, Fig 3d). Hepatic cholesterol levels, in both
esterified (Fig 3e) and unesterified (Fig 3f) form, were affected only in VIR, with slightly but
statistically significantly reduced levels of these lipid species in this group. Consistent with the
observed effects on plasma inflammation markers, infiltration of inflammatory cells was mod-
erately lowered by REF (-29%, n.s.), while VIR strongly and significantly reduced lobular
inflammation (-73%, p0.001 vs CON, p0.001 vs REF; Fig 3g).
Atherosclerosis development is reduced with virgin pumpkin seed oil
Atherosclerotic lesion area and number were quantified histologically in the valve area of the
aortic root. CON diet induced pronounced atherosclerosis with a total lesion area of 143765
Pumpkin Seed Oil Reduces Cardiometabolic Disease
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±17286 μm2 per cross-section (Fig 4a and 4b). The total lesion area was reduced with REF
(100594±14726 μm2, -30%, p0.05, Fig 4a and 4b) and an even stronger effect was observed in
VIR (82766±15164 μm2, -42%, p0.01, Fig 4a and 4b). Refined morphological analysis of
lesion severity revealed that the atherosclerotic lesion area in CON animals was mostly made
up of large and advanced lesions (severe lesion types IV and V; Fig 4c). The observed decrease
in total lesion area with REF and VIR was attributable to a significant reduction in the total
Fig 2. Virgin pumpkin seed oil reduces circulatingmarkers of inflammation in cholesterol-fed
ApoE*3Leidenmice.Mice were fed aWestern type control diet (CON) or CON diet containing 9% refined
pumpkin seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. A: Plasma SAA levels were
reduced by VIR. Liver damage marker B: ASAT and C: ALAT were reduced by VIR but not by REF. D:
Plasma sVCAM-1 levels in VIR animals were lower throughout the duration of the study. Data are mean
±SEM. * p0.05, ** p0.01 compared with CON. # p0.05 for VIR compared with REF.
doi:10.1371/journal.pone.0139196.g002
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area of these severe lesions specifically. Furthermore, immunohistochemical analysis of lesional
macrophage content (MAC-3 positive area) showed that while there was no effect of REF or
VIR on the macrophage content of mild type III lesions (not shown), the macrophage area in
type V (severe) lesions was significantly reduced by both pumpkin seed oils (Fig 4d). In CON
animals, 14.4±3.4% of the type 5 lesion area was MAC-3 positive and this was reduced to 6.16
±1.26% in REF (p0.05 compared with CON) and 8.33±3.0% in VIR (p0.05 compared with
CON). A similar, although non-significant, reduction was observed in type IV lesions (S3 Fig).
The number of lesions (CON: 3.4±0.24; REF: 2.9±0.36; VIR: 2.6±0.21 lesions per cross-section;
S3 Fig) and the percentage of lesion-free aortic segments (CON: 5.6±2.3; REF: 12.2±4.3; VIR:
9.5±3.3%; S3 Fig) were comparable among the groups. However the average size per lesion was
Fig 3. Virgin pumpkin seed oil attenuates development of NAFLD in cholesterol-fed ApoE*3Leidenmice.Mice were fed a Western type control diet
(CON) or CON diet containing 9% refined pumpkin seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. A: Liver weight (expressed as
percentage of terminal body weight) was reduced by REF and VIR. B: representative photomicrographs of HE-stained liver sections show presence of micro-
(grey arrows) and macro- (white arrows)vesicular steatosis and inflammatory cell clusters (black arrows) in CON-fed animals, which was less pronounced in
REF and more strongly reduced in VIR. C: Histological quantitative scoring of macrovesicular steatosis showed significant reduction in VIR. D: Hepatic
triglyceride levels (biochemically determined) were reduced in both REF and VIR while only VIR significantly reduced E: hepatic cholesteryl ester content and
F: free (unesterified) cholesterol levels. G: Histological quantification of number of inflammatory cell aggregates revealed a significant attenuation of hepatic
inflammation by VIR. Data are mean±SEM. * p0.05, ** p0.01, *** p0.001 compared with CON. # p0.05, ### p0.001 for VIR compared with REF.
doi:10.1371/journal.pone.0139196.g003
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significantly reduced by both oils (REF: -25%, p0.05; VIR: -37%, p0.01, Fig 4e), altogether
indicating an effect on lesion growth rather than on the initiation of new lesions.
Both pumpkin seed oils have beneficial effects on hepatic lipid
metabolism while only virgin pumpkin seed oil reduces inflammation
To provide insight into the underlying processes modulated by VIR and REF, hepatic mRNA
expression of genes involved in lipid metabolism and inflammation was analysed.
In line with the observed hypolipidaemic and antisteatotic effects of REF and VIR, expres-
sion of genes involved in lipogenesis was reduced by both pumpkin seed oils (Fig 5a). Expres-
sion of SREBP-1c (Srebf1), a master transcriptional regulator of de novo fatty acid and
triglyceride synthesis [28] was reduced significantly in both REF (fold-change relative to CON:
0.78±0.03, p0.001) and VIR (0.89±0.03, p0.01). In line with this, the expression of the
SREBP-1c target gene Fatty acid synthase (Fasn), the main biosynthetic enzyme in fatty acid
synthesis [29], was also reduced in both REF (0.57±0.07, p0.05) and VIR (0.56±0.09,
p0.01). Expression of Diacylglycerol acyltransferase-1 (Dgat1), which catalyses the final step
in triglyceride synthesis [30], was significantly reduced in REF (0.83±0.03, p0.001), but unaf-
fected in VIR. Together, these results provide indication that the de novo synthesis of lipids is
reduced in pumpkin seed oil-fed animals.
Furthermore, mRNA expression analysis of genes involved in the catabolism of fatty acids
(Fig 5b) revealed that pumpkin seed oil, particularly in its virgin form, may also stimulate the
breakdown of lipids. Expression of Peroxisome proliferator activated receptor α (Ppara), the
Fig 4. Atherosclerosis development is reduced with virgin pumpkin seed oil.Mice were fed a Western type control diet (CON) or CON diet containing
9% refined pumpkin seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. A: representative photomicrographs of HPS-stained cross sections of
the aortic root show pronounced development of atherosclerosis in CON animals, which was less pronounced in REF and strongly reduced by VIR. B:
Morphometric analysis of lesion area revealed a significant decrease in atherosclerotic lesion area by REF and VIR. C: Anti-atherogenic effects of pumpkin
seed oils are specific on severe lesion types. D: Average lesion size was reduced in REF and VIR. E: Immunohistochemical staining for MAC-3 (CD107b)
followed by quantification of positively stained area showed that both REF and VIR reduced the macrophage content of type V lesions. Data are mean±SEM.
* p0.05, ** p0.01 compared with CON.
doi:10.1371/journal.pone.0139196.g004
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Fig 5. Refined and virgin pumpkin seed oils modulate lipid metabolism and inflammatory gene
expression.Mice were fed a Western type control diet (CON) or CON diet containing 9% refined pumpkin
seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. A: Hepatic lipogenic gene expression
(Srebf1, Fasn, Dgat1) was reduced in both REF and VIR. B: Hepatic expression of genes involved in fatty
acid catabolism (Ppara, Cpt1a, Acox1) was upregulated in VIR and to a lesser extent in REF. C. Only VIR
reduced hepatic expression of inflammatory genes (Ccl2, Tnf, IL1b). All gene expression data are expressed
Pumpkin Seed Oil Reduces Cardiometabolic Disease
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main regulator of β-oxidation [31] was increased in both REF (1.27±0.09, p0.05) and VIR
(1.61±0.11, p0.001), with additional beneficial effects of VIR over REF (p0.05). Carnitine
palmitoyl transferase I (Cpt1a), which catalyses the transport of fatty acids into the mitochon-
dria [32] was not increased in REF (1.01±0.07) or VIR (1.16±0.06). Expression of Acyl-CoA
oxidase (Acox1) which catalyses the first step of β-oxidation [33], was unaffected by REF (1.06
±0.05), while it was significantly increased in VIR (1.36±0.04, p0.001). Altogether these
results indicate a stimulating effect of VIR on β-oxidation while the effects of REF on this pro-
cess appear to be less pronounced.
Investigation of hepatic inflammatory gene expression (Fig 5c) revealed an anti-inflamma-
tory effect of VIR specifically, further strengthening the notion that phytochemicals in virgin
pumpkin seed oil rather than the fatty acid composition of the oil per se are responsible for the
observed anti-inflammatory effects. Expression of Monocyte chemoattractant protein-1 (Ccl2),
which plays an important role in the recruitment of myeloid-derived monocytes [34] was not
significantly affected by REF (0.86±0.12), while it was strongly reduced in VIR (0.59±0.10,
p0.05). Similarly, expression of the pro-inflammatory cytokines Tumour necrosis factor
alpha (Tnfa) and Interleukin 1 beta (Il1b) was significantly reduced by VIR (0.59±0.08, p0.05
for Tnfa; 0.70±0.06, p0.05 for Il1b) but not by REF (0.83±0.11 for Tnfa; 0.96±0.10 for Il1b).
Discussion
In the study described herein, we demonstrate the potential long-term health effects of substi-
tution of dietary fat (i.e. replacement of saturated by unsaturated fats), as well as putative addi-
tional effects of phytochemicals present in unrefined (virgin) oil. In a humanised model of
disease, we show that both refined and virgin pumpkin seed oils markedly improve plasma lip-
ids (cholesterol, triglycerides) and virgin pumpkin seed oil also reduced circulating markers of
systemic and vascular inflammation. In the long run, both pumpkin seed oils attenuated the
development of NAFLD and atherosclerosis, with a more pronounced effect of VIR in disease
prevention.
Several epidemiological studies have shown that the development of NAFLD and CVD is
associated with the type of dietary fat consumed [5–7]. To mimic diet-related long-term disease
development in humans, we used the E3L model in which NAFLD and CVD are inducible by
diet. These mice have a humanised lipoprotein profile, and cholesterol feeding results in a
moderate elevation of plasma cholesterol (to about 18–20 mM) and combined development of
NAFLD and atherosclerosis. Under the experimental conditions employed, lipid and inflam-
matory risk markers of future NAFLD and atherosclerosis are already induced after a few
weeks, thus allowing the study of interventions on surrogate markers of disease, under condi-
tions relevant for humans [17, 19, 23, 35].
Replacement of a part of the cocoa butter by pumpkin seed oil markedly diminished the
induction of circulating risk factors (cholesterol, triglycerides, SAA, sVCAM-1), which is in
line with the short-term effects of other pumpkin seed oil preparations tested in humans and
animals [12, 14, 15]. As these studies employed different pumpkin seed oil preparations at dif-
ferent doses and treatment regimens (in capsules or by oral gavage, as an addition to the regu-
lar diet), they provide evidence for a general health benefit of pumpkin seed oil, independent of
how it is prepared and administered (i.e. replacement of dietary fat, or on top of regular diet).
In the present study we exchanged a part of the main fat in the CON diet, which is cocoa
butter (15% w/w of the diet), with pumpkin seed oil (9% w/w of the diet) which modifies the
as fold-change relative to CON. Data are mean±SEM. * p0.05, ** p0.01, *** p0.001 compared with
CON, # p0.05, ### p0.001 for VIR compared with REF.
doi:10.1371/journal.pone.0139196.g005
Pumpkin Seed Oil Reduces Cardiometabolic Disease
PLOS ONE | DOI:10.1371/journal.pone.0139196 September 25, 2015 13 / 19
quality of fat consumed, without affecting the caloric density of the diet. More specifically, the
main fatty acids present in cocoa butter are stearic acid (C18:0, 35.7%), palmitic acid (C16:0,
26.7%) and oleic acid (C18:1n-9, 32.8%), while linoleic acid (C18:2n-6, 2.7%) is only present in
very small amounts. Replacing part of this cocoa butter with pumpkin seed oil, primarily
increases the intake of linoleic acid and reduces the intake of oleic acid and the saturated fatty
acids (SFA) stearic acid and palmitic acid. Linoleic acid is an essential n-6 poly-unsaturated
fatty acid (PUFA) that is reported to have beneficial effects on plasma lipids (reviewed in [36]),
in line with the results described herein. A possible rationale for the observed lipid-lowering
effects may be found in activation of the transcription factor PPAR-α, which is known to be
activated more strongly by PUFA than SFA [37]. Activation of this master regulator of lipid
metabolism reportedly activates beta-oxidation in the liver and lowers plasma triglyceride lev-
els as well as LDL cholesterol [38], consistent with observed reductions in plasma lipids in the
present study. Gene expression analyses in the present study revealed an increased expression
of PPAR-α in both pumpkin seed oil-fed groups, suggesting that transcriptional activity of this
transcriptional regulator may be increased. Virgin pumpkin seed oil had additional effects on
the expression and activation (demonstrated by increased expression of the PPAR-α target
gene Acox1) of PPAR-α relative to the refined oil, indicating that phytochemicals present only
in the virgin oil may have PPAR-α-activating properties. This is in line with findings by others,
showing increased PPAR-α and PPAR-α target gene expression by tocopherols [39] and vari-
ous polyphenol-rich mixtures (e.g. Apple polyphenols [40], Bilberry extract [41] and Walnut
extract [42]). In contrast, there was no additional effect of the virgin oil on the reduction of
lipogenic gene expression, thus indicating that these effects are attributable to the modification
of the fatty acid composition of the diet, rather than effects of bioactive phytochemicals. More
specifically, PUFAs are known to suppress SREBP-1c (the dominant transcriptional regulator
of lipogenic genes) and rates of lipogenesis in rodents [43], in line with the effects of the
PUFA-enriched pumpkin seed oil diets described herein. Remarkably, effects on lipogenic gene
expression were more pronounced in the refined oil than in the virgin oil, suggesting that phy-
tochemicals present in the virgin oil may attenuate these anti-lipogenic effects. Triglyceride
and cholesterol-lowering effects comparable to those observed herein were also reported in
long-term studies in E3L mice treated with long-chain PUFAs [44] or a PUFA-rich food sup-
plement [45], as well as a pharmacological PPAR-α activator [23]. Overall, the reductions of
plasma cholesterol achieved with the pumpkin seed oils are remarkably pronounced (-15% for
REF, -24% for VIR). This effect is in the range typically achieved with low-doses of hypocholes-
terolemic drugs such as HMG-CoA reductase inhibitors (statins) in the E3L mouse as well as
in patients [46, 47].
While both pumpkin seed oils had beneficial effects on dyslipidaemia, only VIR reduced
markers of inflammation SAA and sVCAM-1, indicating that minor components that are pres-
ent in VIR but not in REF may have anti-inflammatory properties. These anti-inflammatory
effects may be conferred by specific phytochemicals, including polyphenolic compounds, of
which virgin pumpkin seed oil is a rich source. The total phenolic content of the VIR prepara-
tion used in the present study was 8-fold higher than in REF. Polyphenols are widely recog-
nised for their anti-inflammatory effects [48–50], and have frequently been reported to be
protective against the development of NAFLD and cardiovascular disease, both in epidemio-
logical and experimental studies [51, 52]. Under comparable experimental conditions and in
the same mouse model, individual polyphenols were found to attenuate atherosclerotic lesion
progression towards severe lesions [19, 35], which is consistent with the observed prevention
of development of severe, vulnerable atherosclerotic lesions with pumpkin seed oil. Pumpkin
seed oil contains a complex mixture of polyphenols and other bioactive phytochemicals and it
is unlikely that observed beneficial effects are confined to a single phytochemical or one single
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mechanism. It is more likely that multiple bioactives affect multiple mechanisms (alone or in
combination) that culminate in the net anti-inflammatory effects observed as has been demon-
strated with other complex mixtures of bioactives [13, 45, 53–55].
Replacement of cocoa butter with pumpkin seed oil reduces the intake of palmitic acid by
50% (from 4% of total diet to 2% of total diet). Although palmitic acid is known to have pro-
inflammatory effects on liver cells, the intake of this fatty acid was comparable in REF and VIR
groups and can thus not explain the marked anti-inflammatory effects of VIR. However, it is
likely that the increased intake in dietary PUFAs and the reduced intake of palmitic acid, as
achieved with both oils, contributed to the reduction of liver inflammation as a marked (29%)
decrease in inflammatory cell content was already observed with REF.
Overall, we show that a simple lifestyle modification, i.e. a switch in the type of fat con-
sumed without reducing total fat or calorie intake, can make a significant contribution to
reducing metabolic and cardiovascular disease risk. Partial replacement of the saturated fat-
rich cocoa butter with refined pumpkin seed oil was sufficient to improve the risk factor dysli-
pidaemia, and affect development of NAFLD and atherosclerosis. Additional anti-inflamma-
tory effects, conferred by minor components present only in the virgin oil, lead to profound
reductions in disease endpoints. Importantly, the observed effects were achieved in a transla-
tional diet-induced disease model, with moderately increased plasma lipids and low-grade met-
abolic inflammation as is typical for high-risk populations in humans. Under these conditions,
pumpkin seed oil represents a powerful means to improve dyslipidaemia, and, particularly
when used in its virgin form, reduce chronic inflammation and prevent long-term disease
development.
Supporting Information
S1 Fig. Refined and virgin pumpkin seed oils do not affect food intake or body weight in
ApoE3Leiden mice.Mice were fed a Western type diet (CON) containing 9% refined pump-
kin seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. A: Average food intake
was measured per cage in group-housed mice (3–4 mice per cage) and did not differ between
groups. B: Body weight was not affected by either VIR or REF and increased gradually over
time. Data are mean±SEM.
(TIF)
S2 Fig. Refined and virgin pumpkin seed oils do not affect microvesicular steatosis in
ApoE3Leiden mice.Mice were fed a Western type diet (CON) containing 9% refined pump-
kin seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. Microvesicular hepatos-
teatosis (% of total liver cross section affected) was not reduced by REF or VIR. Data are mean
±SEM.
(TIF)
S3 Fig. Refined and virgin pumpkin seed oils do not affect number of lesions or lesion-free
segments ApoE3Leiden mice.Mice were fed a Western type diet (CON) containing 9%
refined pumpkin seed oil (REF) or 9% virgin pumpkin seed oil (VIR) for 20 weeks. A: Immu-
nohistochemical staining for MAC-3 (CD107b) followed by quantification of positively stained
area showed that the macrophage content of type IV lesions was not significantly reduced by
REF or VIR. B: number of lesions per cross section were not reduced by REF or VIR. C: REF
and VIR did not increase the percentage of lesion-free segments. Data are mean±SEM
(TIF)
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